CLClinicLens

Infectious Disease

Phase I dose-ascending, safety, and pharmacokinetics study of APC148, a novel metallo-β-lactamase inhibitor, in healthy volunteers. | ClinicLens

APC148 is a novel metallo-β-lactamase inhibitor with broad activity against Ambler class B enzymes, including NDM, VIM, and IMP. It is being developed for patients with serious infections caused by multidrug-resistant, gram-negative bacteria. APC148 is combined with the broad-spe

Medical Literature · Updated

← Back to articles
This standalone article is served from the ClinicLens content archive.

If the embedded page does not load in your browser, open it directly.